Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Myopia
Share your love
AEVR’s executive director on #SeeWhatMatters and safeguarding the National Eye Institute
#SeeWhatMatters is a national advocacy campaign to raise awareness about the importance of federally funded vision research and to protect the independence of the National Eye Institute amid proposed structural changes to the NIH. (Image courtesy of #SeeWhatMatters) The Alliance…
Lifestyle and sleep-related behaviours in children with myopia – BMC Ophthalmology
Lifestyle and sleep-related behaviours in children with myopia BMC Ophthalmology Source: Author: | Date: 2025-02-26 08:00:00 Source: Author: | Date: 2025-02-26 08:00:00
OneSight and WHO Partner on SPECS 2030
The OneSight EssilorLuxottica Foundation has entered a strategic partnership with the World Health Organization (WHO) as a global collaborator in the SPECS 2030 initiative. This alliance aims to expedite progress toward achieving the first global target for effective refractive error…
Global Myopia Surge in Children Predicted to Hit 740M by 2050
A new analysis published in the British Journal of Ophthalmology reveals that nearly one in three children and teens worldwide is expected to be affected by myopia by 2050, translating to over 740 million cases. This trend reflects a significant…
Ray Tracing Optimization – Myopic LASIK & AI
Laser-assisted in situ keratomileusis (LASIK) has become one of the most effective and safe methods for correcting refractive error with laser corneal intervention, as evidenced by the long and large number of publications in the peer-reviewed literature. In recent years,…
Eyenovia Pediatric Myopia Trial Falls Short
Eyenovia has announced that its Phase 3 CHAPERONE study, aimed at treating pediatric progressive myopia, failed to meet its primary endpoint. The trial evaluated the company’s proprietary drug-device combination using low-dose atropine delivered via the Optejet platform. A review by…
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Sydnexis Appoints Perry J. Sternberg as CEO
Sydnexis, Inc., a pioneering biopharmaceutical company dedicated to addressing pediatric myopia progression, has appointed Perry J. Sternberg as its Chief Executive Officer and as a member of its Board of Directors. Sternberg, a seasoned pharmaceutical and biotech executive with over…
What Is Staphyloma? | OBN
Staphyloma is a bulging or protrusion of the eye’s inner layers through a thinned area of the outer layers. It is typically caused by a structural weakness in the eye, and it can lead to vision problems if left untreated.…
The Effects of Screen Time on Children’s Eyes
The increasing prevalence of digital devices in children’s lives has sparked a growing concern among parents, educators, and healthcare professionals about the potential impacts on eye health. As screens become an integral part of education, entertainment, and social interaction, understanding…